a, a N Clinical Trials

A listing of a, a N clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1863 clinical trials
Effect of a Dietary Iron Program on Iron Status and IQ in Children in Phatthalung Province, Thailand123  

Iron deficiency (ID) continues to be one of the most prevalent disorders, which can adversely affect cognitive ability in childhood. Our aim was to determine the effect of a dietary iron education program (DIP) on children's iron status and intelligence quotient (IQ) score. This pre-test (week 1) post-test (week 16) …

Accepts healthy volunteers
  • 0 views
  • 23 Aug, 2024
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

The subject will receive AK104 450mg Q2W until unacceptable toxicity, confirmed disease progression, withdrawal of consent, or for a maximum of 24 months.

refractory peripheral t-cell lymphoma
lymphoma
peripheral t-cell lymphoma
cancer
t-cell lymphoma
  • 0 views
  • 19 Feb, 2024
A Study of Itolizumab (EQ001) to Evaluate the Safety Tolerability PK PD and Clinical Activity in Uncontrolled Asthma

This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with moderate-to-severe asthma.

forced expiratory volume
fluticasone
bronchial provocation test
anticholinergics
albuterol
  • 0 views
  • 20 Sep, 2024
  • 4 locations
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.

oxygen saturation
lymphoblastic leukemia
lymphoma
cancer
diffuse large b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

This is a open-labeled, single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with radiotherapy in patients with early triple-negative breast cancer.

mastectomy
camrelizumab
serum bilirubin level
cancer
metastasis
  • 0 views
  • 19 Feb, 2024
Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Injections (DGS)  

A prospective, randomized, single blind, two-arms, multicenter study. The study aims to assess the safety of a dosing-guided system (DGS) that provides direct advice on insulin dosing recommendations and diabetes management to individuals with diabetes using insulin or starting basal insulin therapy, guided by their continuous glucose monitoring (CGM).

  • 0 views
  • 13 May, 2025
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.

SARS
chest x-ray
nitric oxide
ct scan
acute respiratory syndrome (sars)
  • 0 views
  • 19 Feb, 2024
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

oxygen saturation
lymphoblastic leukemia
lymphoma
cancer
diffuse large b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will be done in two phases. Phase 1a of this …

myeloid leukemia
myelodysplastic syndromes
cancer therapy
exhausted
leukemia
  • 0 views
  • 19 Feb, 2024
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

KEAP1/NRF2 mutation status (for eligibility) and STK11/LKB1 status (for stratification) will be determined by next generation sequencing. A commercial liquid biopsy (circulating tumor DNA) NGS test will be provided to study participants free of charge.

liquid biopsy
BRAF
measurable disease
systemic therapy
metastasis
  • 0 views
  • 19 Feb, 2024